{
  "version": "1.0",
  "exported_at": "2026-01-12T10:00:00.000000",
  "source": "rag-chat-pipeline",
  "next_phase": "drug-discovery-pipeline",
  "count": 5,
  "targets": [
    {
      "id": "TH-20260112-VCP-FTD",
      "gene": "VCP",
      "protein": "Valosin-containing protein (p97)",
      "uniprot_id": "P55072",
      "rationale": "VCP (p97) is an AAA+ ATPase critical for protein quality control. Mutations cause IBMPFD (Inclusion Body Myopathy with Paget disease and Frontotemporal Dementia). VCP is a validated drug target with inhibitors in development including CB-5083.",
      "therapeutic_area": "Neurodegeneration",
      "mechanism": "AAA+ ATPase inhibition to modulate protein homeostasis",
      "confidence": "high",
      "priority": 5,
      "variant_count": 1,
      "pdb_ids": [
        "5FTK",
        "5FTJ",
        "5FTI"
      ],
      "status": "validated",
      "reference_compounds": [
        {
          "name": "CB-5083",
          "smiles": "CC1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5F",
          "mechanism": "VCP/p97 inhibitor",
          "status": "Clinical development (discontinued due to off-target effects)"
        }
      ]
    },
    {
      "id": "TH-20260109183212-EGFR",
      "gene": "EGFR",
      "protein": "Epidermal growth factor receptor",
      "uniprot_id": "P00533",
      "rationale": "Key oncology target with known druggable kinase domain. Multiple approved inhibitors.",
      "therapeutic_area": "Oncology",
      "mechanism": "Tyrosine kinase inhibition",
      "confidence": "high",
      "priority": 5,
      "variant_count": 0,
      "pdb_ids": [
        "7SYE",
        "1M17"
      ],
      "status": "validated"
    },
    {
      "id": "TH-20260109183212-BRAF",
      "gene": "BRAF",
      "protein": "B-Raf proto-oncogene",
      "uniprot_id": "P15056",
      "rationale": "V600E mutation is highly druggable with approved inhibitors.",
      "therapeutic_area": "Oncology",
      "mechanism": "Kinase inhibition",
      "confidence": "high",
      "priority": 5,
      "variant_count": 0,
      "pdb_ids": [
        "6P3D",
        "4MNE"
      ],
      "status": "validated"
    },
    {
      "id": "TH-20260109183212-KRAS",
      "gene": "KRAS",
      "protein": "GTPase KRas",
      "uniprot_id": "P01116",
      "rationale": "G12C mutation targetable with covalent inhibitors.",
      "therapeutic_area": "Oncology",
      "mechanism": "Covalent GTPase inhibition",
      "confidence": "high",
      "priority": 4,
      "variant_count": 0,
      "pdb_ids": [
        "6OIM"
      ],
      "status": "validated"
    },
    {
      "id": "TH-20260109183212-PIK3CA",
      "gene": "PIK3CA",
      "protein": "PI3K catalytic subunit alpha",
      "uniprot_id": "P42336",
      "rationale": "PI3K pathway target with approved inhibitor alpelisib.",
      "therapeutic_area": "Oncology",
      "mechanism": "Lipid kinase inhibition",
      "confidence": "medium",
      "priority": 4,
      "variant_count": 0,
      "pdb_ids": [
        "4JPS"
      ],
      "status": "hypothesis"
    }
  ]
}
